LL-37
Also known as: Cathelicidin · hCAP18
An endogenous cathelicidin antimicrobial peptide that serves as the immune system's first line of defense against bacteria, fungi, and biofilms including MRSA.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~4 hours
100–200 mcg
Subcutaneous injection
Mechanism of Action
Disrupts microbial membranes through electrostatic binding, while simultaneously modulating innate immune response and promoting epithelial tissue regeneration.
Key Research Areas
Frequently Asked Questions
What is LL-37?▾
How does LL-37 work?▾
What is the recommended dosage for LL-37?▾
What is the half-life of LL-37?▾
Is LL-37 FDA approved?▾
Research Disclaimer
The information provided about LL-37 is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.